Exozymes Inc.
EXOZ- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002010788
In the last 90 days, Exozymes Inc. insiders filed 1 open-market purchase and 0 sales; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.05M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $6.41K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 9
- 13F valueReported value at the end of Q2 2026
- $1.05M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding EXOZ, Q2 2026
No superinvestor reported holding EXOZ at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Exozymes Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 (view filing)7:33 PM ET | Aug 25-26 | 8 daysLate | Heltzen MichaelChief Executive Officer | PPurchase | +855 | $7.49 | +$6.41K | +6.5%14.0K after | 5 lots |
| Apr 10, 2026 (view filing) | Apr 8-9 | 2 days | Korman Tyler PazChief Scientific Officer | SSale | −1.50K | $10.29 | −$15.4K | −0.2%729.1K after | 2 lots |
| Jul 2, 2025 (view filing) | Jul 2 | Same day | Heltzen MichaelChief Executive Officer | PPurchase | +1.04K | $10.22 | +$10.6K | +10.8%10.6K after | |
| Jan 21, 2025 (view filing) | Jan 16-17 | 5 days | Heltzen MichaelChief Executive Officer | PPurchase | +1.89K | $10.78 | +$20.3K | +95.2%3.87K after | 2 lots |
| Nov 19, 2024 (view filing) | Nov 15 | 4 days | Heltzen MichaelChief Executive Officer | PPurchase | +1.98K | $11.10 | +$22.0K | New position1.98K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Exozymes Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 54,985 | $463.5K | 0.00% | +32,795+147.8% | Added |
| Davidson Kahn Capital Management, LLC | 25,000 | $210.8K | 0.09% | +25,000 | New |
| Geode Capital Management, LLC | 23,406 | $197.3K | 0.00% | +1,515+6.9% | Added |
| BlackRock, Inc. | 9,610 | $81.0K | 0.00% | +2,813+41.4% | Added |
| Vanguard Fiduciary Trust Co | 9,426 | $79.5K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 1,250 | $10.5K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 349 | $2.94K | 0.00% | −968−73.5% | Reduced |
| UBS Group AG | 203 | $1.71K | 0.00% | +179+745.8% | Added |
| Barclays PLC | 75 | $632 | 0.00% | +75 | New |